Given that peroxisome proliferator-activated receptor gamma (PPARγ) activation reduces STAT5 expression levels [54], PPARγ activators, including glitazones and pioglitazone, combined with IM, have been shown to clear residual CMLSCs, as confirmed in phase II clinical trials in patients with CML (ClinicalTrials.gov ID: NCT02888964, NCT02889003) [55]. This evidence concerns the gene PPARG and chronic myelogenous leukemia, BCR-ABL1 positive.